Suppr超能文献

HIV 感染者的黏膜分泌物和血清中的体液免疫反应。

Humoral immune responses to HIV in the mucosal secretions and sera of HIV-infected women.

机构信息

Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL, USA; Institute of Immunology and Microbiology, Faculty of Medicine, Charles University, Prague, Czech Republic.

出版信息

Am J Reprod Immunol. 2014 Jun;71(6):600-7. doi: 10.1111/aji.12203. Epub 2014 Feb 5.

Abstract

Although sera and all external secretions contain antibodies to human immunodeficiency virus (HIV), their levels, specificity, isotypes, and relevant effector functions display a great degree of variability. Antibodies that bind HIV antigens and neutralize the virus are predominantly associated with the IgG isotype in sera and in all external secretions, even where total levels of IgG are much lower than those of IgA. Rectal fluid that contains high IgA, but low IgG levels, displayed low neutralizing activity independent of antibodies. Therefore, external secretions should be evaluated before and after selective depletion of Ig. At the systemic level, HIV-specific IgA may interfere with the effector functions of IgG, as suggested by recent studies of individuals systemically immunized with an experimental HIV vaccine. Although HIV-specific IgG and IgA antibodies may exhibit their protective activities at mucosal surfaces through interference with viral entry and local neutralization at the systemic level, such antibodies may display discordant effector functions.

摘要

虽然血清和所有外分泌液都含有针对人类免疫缺陷病毒 (HIV) 的抗体,但它们的水平、特异性、同种型和相关效应功能显示出很大的可变性。与 HIV 抗原结合并中和病毒的抗体主要与血清和所有外分泌液中的 IgG 同种型相关,即使 IgG 的总水平远低于 IgA。含有高 IgA 但 IgG 水平低的直肠液显示出独立于抗体的低中和活性。因此,在选择性耗尽 Ig 之前和之后,应该对外分泌液进行评估。在系统水平上,如最近对用实验性 HIV 疫苗进行全身免疫的个体进行的研究所示,HIV 特异性 IgA 可能会干扰 IgG 的效应功能。尽管 HIV 特异性 IgG 和 IgA 抗体可以通过干扰病毒进入和局部中和在系统水平上显示其在粘膜表面的保护活性,但这些抗体可能表现出不同的效应功能。

相似文献

1
Humoral immune responses to HIV in the mucosal secretions and sera of HIV-infected women.
Am J Reprod Immunol. 2014 Jun;71(6):600-7. doi: 10.1111/aji.12203. Epub 2014 Feb 5.
2
Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection.
EBioMedicine. 2016 Dec;14:97-111. doi: 10.1016/j.ebiom.2016.11.024. Epub 2016 Nov 21.
4
Paucity of antigen-specific IgA responses in sera and external secretions of HIV-type 1-infected individuals.
AIDS Res Hum Retroviruses. 2004 Sep;20(9):972-88. doi: 10.1089/aid.2004.20.972.
5
Mucosal antibody responses to HIV.
Methods Mol Biol. 2009;485:333-45. doi: 10.1007/978-1-59745-170-3_22.
6
IgA immunity in HIV type 1-infected chimpanzees. I. Systemic immunity.
AIDS Res Hum Retroviruses. 1997 Oct 10;13(15):1263-72. doi: 10.1089/aid.1997.13.1263.
7
Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines.
Clin Vaccine Immunol. 2014 Aug;21(8):1023-36. doi: 10.1128/CVI.00230-14. Epub 2014 Jun 11.
9
Comparison of the distribution of IgG and IgA antibodies in serum and various mucosal fluids of HIV type 1-infected subjects.
AIDS Res Hum Retroviruses. 1999 Oct 10;15(15):1365-76. doi: 10.1089/088922299310070.

引用本文的文献

本文引用的文献

1
The Neonatal Fc receptor (FcRn) enhances human immunodeficiency virus type 1 (HIV-1) transcytosis across epithelial cells.
PLoS Pathog. 2013;9(11):e1003776. doi: 10.1371/journal.ppat.1003776. Epub 2013 Nov 21.
2
Synthetic glycopeptides reveal the glycan specificity of HIV-neutralizing antibodies.
Nat Chem Biol. 2013 Aug;9(8):521-6. doi: 10.1038/nchembio.1288. Epub 2013 Jun 30.
3
A nonparametric procedure for defining a new humoral immunologic profile in a pilot study on HIV infected patients.
PLoS One. 2013;8(3):e58768. doi: 10.1371/journal.pone.0058768. Epub 2013 Mar 22.
4
Comparative Evaluation of HIV-1 Neutralization in External Secretions and Sera of HIV-1-Infected Women.
Open AIDS J. 2012;6:293-302. doi: 10.2174/1874613601206010293. Epub 2012 Dec 28.
5
Inhibitory effect of HIV-specific neutralizing IgA on mucosal transmission of HIV in humanized mice.
Blood. 2012 Nov 29;120(23):4571-82. doi: 10.1182/blood-2012-04-422303. Epub 2012 Oct 11.
7
Immune-correlates analysis of an HIV-1 vaccine efficacy trial.
N Engl J Med. 2012 Apr 5;366(14):1275-86. doi: 10.1056/NEJMoa1113425.
8
The Antibody Response against HIV-1.
Cold Spring Harb Perspect Med. 2012 Jan;2(1):a007039. doi: 10.1101/cshperspect.a007039.
9
Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.
Cold Spring Harb Perspect Med. 2011 Sep;1(1):a007278. doi: 10.1101/cshperspect.a007278.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验